1255206-75-7

Basic information

• Product Name: 5-(2-bromoacetyl)-4-methylisobenzofuran-1(3H)-one
• Synonyms: 5-(2-bromoacetyl)-4-methylisobenzofuran-1(3H)-one
• CAS NO: 1255206-75-7
• Molecular Formula: C11H9BrO3
• Molecular Weight: 269.09136
• Mol File: 1255206-75-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(2-bromoacetyl)-4-methylisobenzofuran-1(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2-bromoacetyl)-4-methylisobenzofuran-1(3H)-one(1255206-75-7)
• EPA Substance Registry System: 5-(2-bromoacetyl)-4-methylisobenzofuran-1(3H)-one(1255206-75-7)

Safety Data

• Hazardous Substances Data: 1255206-75-7(Hazardous Substances Data)

Upstream product

• 1255206-74-6 5-(1-butoxy-vinyl)-4-methyl-3H-isobenzofuran-1-one 
• 603-80-5 3-hydroxy 2-methylbenzoic acid 
• 54874-26-9 3-hydroxymethyl-2-methylphenol 
• 1255206-72-4 6-bromo-3-hydroxy-2-methylbenzenemethanol 
• 1194700-73-6 5-hydroxy-4-methyl-3H-isobenzofuran-1-one 
• 1255206-73-5 trifluoromethanesulfonic acid 4-methyl-1-oxo-1,3-dihydro-isobenzofuran-5-yl ester 

Downstream Products

• 1255206-70-2 4-methyl-5-[2R-oxiran-2-yl]-2-benzofuran-1(3H)-one 
• 1446520-36-0 tert-butyl 4-[2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)-2-oxoethyl]-3-oxopiperazine-1-carboxylate 

Relevant articles and documents

Bio- And Chemocatalysis for the Synthesis of Late Stage SAR-Enabling Intermediates for ROMK Inhibitors and MK-7145 for the Treatment of Hypertension and Heart Failure

A synthetic strategy to provide two late-stage intermediates for the synthesis of diverse analogues of ROMK inhibitors for the treatment of hypertension and heart failure is described. Key transformations include carbonylation of a bromoarene, regioselect

Method for preparing ROMK inhibitor intermediate

The invention relates to a method for preparing a chiral glycidyl substituted benzoheterocycle compound as shown in the formula (I). The compound represented by the formula (I) can serve as a key chiral intermediate of a renal outer medullary potassium channel (ROMK) inhibitor. Please see the formula (I) in the description, wherein n is 1 or 2 or 3, and R1, R2 and R3 are selected from hydrogen, C1-C6 straight-chain or branched alkyl, C2-C8 straight-chain or branched alkynyl and 3-8-membered alicyclic groups.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Disclosed are compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Inhibitors of the renal outer medullary potassium channel

This invention relates to compounds of Formula I having the following general structure: [in-line-formulae]Z1—Y1—(CH2)n1—R—(CH2)n2—Y2—Z2 [/in-line-formulae] wherein R

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis